Dr. Patrick Kevin Gleeson, MD

Dr. Gleeson practices at Good Shepherd Penn Partners - HOPD (3737 Market St, 2nd Fl) in Philadelphia, Pennsylvania.

Dr. Gleeson's NPI, 1124406889, was assigned on May 14, 2015. Dr. Gleeson graduated from Pennsylvania State University College of Medicine in 2015. Dr. Gleeson holds Pennsylvania license MD466426.

Dr. Gleeson's primary practice is Good Shepherd Penn Partners - HOPD (3737 Market St, 2nd Fl), at 3737 Market St, 2nd Fl, Philadelphia, PA 19104.

Dr. Gleeson's primary practice is Good Shepherd Penn Partners - HOPD (3737 Market St, 2nd Fl) in Philadelphia, Pennsylvania. Dr. Gleeson is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Gleeson to 1 more hospital, 1 breast imaging center, 1 group practice or clinic and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gleeson practices, 6 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Gleeson's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Gleeson is board certified in internal medicine by the American Board of Internal Medicine. Dr. Gleeson is licensed in Pennsylvania.

CMS data shows 19 Medicare services from Dr. Gleeson across 1 procedure code in 2024, all of them office visits, for 26 Medicare patients. Medicare paid $1,381 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 26 Medicare patients who saw Dr. Gleeson in 2024. The largest group is 65 to 74, with 15 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gleeson's median patient age at 41, with 73% women.

In 2024, Dr. Gleeson wrote 316 Medicare Part D claims for 34 patients. 54% of them were for generic drugs. CMS names the drug for 234 of them, across 10 drugs with 11 or more claims each, at $318,155 in total drug cost. In 2023, CMS named 196 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Gleeson for performance year 2024, reported as part of a group. Dr. Gleeson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gleeson as offering telehealth.

Dmand AI links 19 papers to Dr. Gleeson, published from 2019 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Asthma, Administration, Inhalation and Drug Hypersensitivity. Dr. Gleeson has published most often in J Allergy Clin Immunol Pract. Dr. Gleeson's most frequent co-authors are Andrea Joan Apter, MD, Olajumoke Olanrewaju Fadugba, MD and Nithin Dev Adappa, MD.

CMS Open Payments shows 27 general payments to Dr. Gleeson from 8 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $346.

Dr. Gleeson graduated from Pennsylvania State University College of Medicine in 2015.